

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Single Technology Appraisal**

# Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer ID1333

### **Provisional Stakeholder List**

Commentators (no right to submit or
appeal)
General
<ul> <li>All Wales Therapeutics and Toxicology</li> </ul>
Centre
Allied Health Professionals Federation
Board of Community Health Councils in
Wales
British National Formulary     One Overlite Communication
Care Quality Commission  Paragraphy of the aller Considers
Department of Health, Social Services     and Public Sefety for Northern Iroland
and Public Safety for Northern Ireland
<ul><li>Healthcare Improvement Scotland</li><li>Medicines and Healthcare products</li></ul>
Regulatory Agency
<ul> <li>National Association of Primary Care</li> </ul>
National Pharmacy Association
NHS Confederation
Scottish Medicines Consortium
Welsh Government
Welsh Health Specialised Services
Committee
Possible comparator companies
<ul> <li>Bristol Myers Squibb Pharmaceuticals</li> </ul>
limited (nivolumab)
Celgene (paclitaxel)
Hospira UK Ltd (docetaxel, paclitaxel)
Merck, Sharp & Dohme     (nambrolizumah)
<ul><li>(pembrolizumab)</li><li>Roche (atezolizumab)</li></ul>
<ul><li>Roche (atezolizumab)</li><li>Seacross Pharmaceuticals (docetaxel,</li></ul>
paclitaxel)
Teva UK Limited (paclitaxel)
(pasinario)
Relevant research groups
Cochrane UK
Cochrane Urology

Provisional stakeholder list for the evaluation of erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer ID1333



Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Society of Urogynaecology</li> <li>British Uro-Oncology Group</li> <li>Cancer Research UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> <li>Urology Foundation</li> </ul>	<ul> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
Others  Department of Health and Social Care  NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).


#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

Provisional stakeholder list for the evaluation of erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer ID1333

Issue date: January 2024





and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.